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Abstract
Background
Patients with severe community-acquired pneumonia (SCAP) and life-threatening acute
respiratory failure may require invasive mechanical ventilation (IMV). Since use of IMV is
often associated with significant morbidity and mortality, we assessed whether patients
invasively ventilated would represent a target population for interventions aimed at reducing
mortality of SCAP.
Methods
We prospectively recruited consecutive patients with SCAP for 12 years. We assessed the
characteristics and outcomes of patients invasively ventilated at presentation of pneumonia,
compared with those without IMV, and determined the influence of risks factors on mortality
with a multivariate weighted logistic regression using a propensity score.
Results
Among 3,719 patients hospitalized with CAP, 664 (18%) had criteria for SCAP, and 154
(23%) received IMV at presentation of pneumonia; 198 (30%) presented with septic shock.
In 370 (56%) cases SCAP was diagnosed based solely on the presence of 3 or more IDSA/
ATS minor criteria. Streptococcus pneumoniae was the main pathogen in both groups. The
30-day mortality was higher in the IMV, compared to non-intubated patients (51, 33%, vs.
94, 18% respectively, p<0001), and higher than that predicted by APACHE-II score (26%).
IMV independently predicted 30-day mortality in multivariate analysis (adjusted odds-ratio
354, 95% confidence interval 145–837, p = 0006). Other independent predictors of mor-
tality were septic shock, worse hypoxemia and increased serum potassium.
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Conclusion
Invasive mechanical ventilation independently predicted 30-day mortality in patients with
SCAP. Patients invasively ventilated should be considered a different population with higher
mortality for future clinical trials on new interventions addressed to improve mortality of
SCAP.
Introduction
Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality [1].
The definition of severe CAP (SCAP) is not univocal and this classification includes a hetero-
geneous group of patients. The criteria currently used to define SCAP in the guidelines are
based on the presence of severe acute respiratory failure (ARF) needing invasive mechanical
ventilation (IMV) and/or septic shock with organ system dysfunction [1,2]. Alternatively, sev-
eral minor criteria requiring a high intensity monitoring and treatment have been proposed
[1].
Severe CAP is associated with significant mortality, and despite effective antibiotic therapy,
16% to 36% patients may die within a short period of time [3–5]. Therefore, efforts to improve
mortality of SCAP should be directed to select populations of patients at high risk of mortality.
Patients with SCAP and life-threatening ARF may require IMV [6]. However, the use of
IMV is associated with multiple complications [7,8] and a high mortality [9]. The need for
IMV may also be a marker of more severe acute disease regardless the use of this life-support
measure. However, no prospective studies have comprehensively assessed the impact of IMV
in consecutive series of patients with SCAP.
We hypothesized that IMV in patients with SCAP would result in worse outcomes regard-
less of their initial clinical severity. The aim of this study was therefore to identify a population
of patients with SCAP characterized by a high mortality that could benefit from future clinical
trials on treatments aimed at reducing mortality. Since IMV is a major determinant of CAP
severity, and IMV is associated with higher mortality in patients with SCAP, we divided the
population according to the use for IMV or not. Furthermore, we studied the risk factors for
mortality, including invasive ventilatory support, in this critically ill population.
Methods
Patients
A prospective observational study was conducted at Hospital Clinic of Barcelona. All consecu-
tive cases of CAP admitted from the Emergency Department between January-2000 and
December-2011 were registered, and we selected all cases with SCAP. For publication pur-
poses, the study was approved by the Ethics Committee of our institution (Comité Ètic d’Inves-
tigació Clínica, register: 2009/5451). Written informed consent was waived because of the non-
interventional design.
Pneumonia was defined as a new pulmonary infiltrate on the admission chest radiograph,
and symptoms and signs of lower respiratory tract infection. The exclusion criteria were: a)
severe immunosuppression (human immunodeficiency virus infection, active solid or hemato-
logical neoplasm treated with chemotherapy, oral corticosteroid treatment with 20 mg or
more prednisone-equivalent per day for at least two weeks, and other immunosuppressive
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drugs); b) active tuberculosis; c) a confirmed alternative diagnosis; and d) criteria of health-
care associated pneumonia [10].
Severe CAP was defined according to the 2007 Infectious Disease Society of America/
American Thoracic Society guidelines [1]. Patients presenting within the first 48 hours of hos-
pital admission at least one major criteria, either septic shock or use of IMV or, in absence of
major criteria, patients with at least three minor criteria, as described in Table 1, were selected
for the present study. Presentation of these severity criteria after this period of time was con-
sidered clinical worsening. Because blood urea nitrogen level is not systematically determined
in our hospital, we accepted, in its place, serum creatinine level>1.5 mg/dL [3,11].
The decisions to initiate IMV were taken by the attending physicians, based on the presence
of any of the following intubation criteria: respiratory or cardiac arrest, respiratory pauses with
loss of alertness or gasping for air, severely impaired consciousness, major agitation inade-
quately controlled by sedation, signs of exhaustion, massive aspiration, inability to manage
respiratory secretions appropriately, and hemodynamic instability without response to fluids
and vasoactive agents [12]. In addition, patients were also intubated in case of subsequent
worsening of gas exchange or respiratory distress despite supportive measures.
Data collection
The following parameters were recorded at admission: age, sex, current or former smoking
(>10 pack-years), current or former alcohol (>80 g/day for at least one year before presenta-
tion) and drug consumption, co-morbidities, antibiotic treatment within 30 days before
hospital admission, previous treatment with inhaled and systemic corticosteroids, clinical
parameters, arterial blood gases, chest radiograph findings, including pleural effusion, labora-
tory parameters, adequacy of empiric antibiotic therapy, use of IMV, other clinical events (sep-
tic shock, acute renal failure). Admission to intensive care units (ICU), which included
intermediate care units, the length of stay, and 30-day mortality were also noted. We also cal-
culated the Acute Physiology And Chronic Health Evaluation (APACHE)-II score [13], the
Table 1. Frequency of severity criteria in the study population at presentation of pneumonia.
Severity criteria n = 664
Major criteria
Use of invasive mechanical ventilation 154 (23)
Septic shock 198 (30)
Minor criteria
PaO2/FiO2 250
 392 (59)
Respiratory rate30 breaths/min  373 (56)
Creatinine level >15 mg/dL 357 (54)
Confusion/disorientation 318 (48)
Multilobar radiologic infiltrates 296 (45)
Hypotension (not meeting septic shock criteria) 101 (15)
Core temperature <36˚C 72 (11)
White blood cell counts <4,000 cells/mm3 47 (7)
Platelet count <100,000 cells/mm3 26 (4)
Results are given as n (%).
 The use of non-invasive mechanical ventilation can substitute for respiratory rate30 breaths/min or PaO2/FiO2
250 [1].
https://doi.org/10.1371/journal.pone.0191721.t001
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Pneumonia Severity Index (PSI) [14], and the CURB-65 (Confusion, elevated blood Urea
nitrogen, Respiratory rate and Blood pressure plus age65 years) score [15,16] at admission.
Microbiologic evaluation
Sputum and two blood samples were obtained for bacterial culture before start of antibiotic
therapy in the Emergency Department. Nasopharyngeal swabs for respiratory virus detection
and urine samples for Streptococcus pneumoniae and Legionella pneumophila antigen detection
were obtained within 24 hours after hospital admission. Pleural puncture, tracheobronchial
aspirates and bronchoalveolar lavage fluid, when available, were collected for Gram and Ziehl–
Nielsen stains and cultured for bacterial, fungal and mycobacterial pathogens. Blood samples
for serology of atypical pathogens and respiratory virus was performed at admission and
within the third and sixth weeks thereafter. Additional details and the criteria for etiologic
diagnosis have been extensively described [17].
Statistical analysis
We showed n (%) for categorical variables and mean±SD for continuous variables. Categorical
variables were compared with the chi-square test or the Fisher exact test. Continuous variables
were compared between 2 groups using the t-test or the analysis of variance (ANOVA) was
used when comparing more than 2 groups. The ICU and hospital stay are shown as median
(interquartile range), and were compared with the Mann-whitney non-parametric test due to
the non-normally distributed values.
In addition to compare the characteristics and outcomes of patients with and without IMV,
we distinguished those who met the major criteria from those who met the minor criteria
only, according to IDSA/ATS 2007 definition [1].
Generalized linear model (GLM) analyses [18] were performed to determine the influence
of the risks factors on 30-day mortality. Models were defined using a binomial probability dis-
tribution and a logit link function, using inverse probability of treatment weights (IPTWs)
[19] to account for biases due to observed confounders. In a first step, each risk factor (age,
smoking and alcohol consumption, co-morbidities, confusion/disorientation, multilobar infil-
tration, APACHE-II, PSI risk class, CURB-65, laboratory and blood gas variables, adequacy of
empiric antibiotic therapy, shock, and use of IMV) was tested individually. In a second step, a
propensity score (PS) for patients with IMV were developed. The PS was determined, irrespec-
tive of the outcome, through a multivariate logistic regression to predict the influence of 16
predetermined variables on the use of IMV. Variables were chosen for inclusion in the PS cal-
culation according to the methods of Brookhart et al [20] and included variables associated
with IMV use and outcome (age, gender, previous antibiotics, smoking and alcohol consump-
tion, chronic respiratory, cardiovascular, neurological, renal, and liver disease, diabetes melli-
tus, APACHE-II, multilobar infiltration, pleural effusion, acute renal failure, and adequacy of
empiric antibiotic therapy). IPTW used the PS to form a weight. The weights were finally
incorporated in the multivariate weighted logistic regression model to predict 30-day mortal-
ity, including all risk factors which showed an association in the univariate analyses (p<010),
and calculated in a stepwise backward elimination procedure, dropping non-significant vari-
ables until no further improvement of the Akaike’s information criterion was achieved [21].
The odds-ratio (OR) and 95% confidence intervals (CI) were calculated. Variables highly cor-
related were excluded from multivariate analyses. Goodness-of-fit information was given for
the Pearson chi-square test to assess the overall fit of the model. The area under the receiver
operating characteristic (ROC) curve of the multivariate model to predict 30-day mortality
was calculated. All analyses were performed using the Observed Cases approach.
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The level of significance was set at 005 (two-tailed). All analyses were performed with IBM
SPSS Statistics 20.0 (Armonk, New York).
Results
Patients’ characteristics
Among 3,719 patients with CAP diagnosis during the study period, 664 (18%) had criteria for
SCAP; of those, 154 (23%) required IMV during the current hospital admission (Fig 1).
Ninety-four (18%) patients without IMV had received non-invasive ventilation (NIV). The
diagnosis of SCAP was based on the presence of major severity criteria in 294 (44%) cases; 154
patients were invasively ventilated and 198 had septic shock, with 58 having both major crite-
ria. In 370 (56%) cases the diagnosis of SCAP was based solely on the presence of 3 or more
minor criteria. The frequency of severity criteria in our population is shown in Table 1.
Patients from the IMV group were younger, had received less frequently previous antibiot-
ics and influenza vaccine, at hospital admission they had higher heart rate and diastolic blood
pressure, worse baseline oxygenation, higher arterial CO2 tension (PaCO2), lower arterial pH
and CURB-65 score, less frequently acute renal failure, and a higher rate of pleural effusion
and septic shock, with a trend to less frequent previous treatment with inhaled corticosteroids,
and lower white blood cell count and hematocrite, compared to patients without IMV (Tables
2 and 3).
Microbiologic findings
An etiologic diagnosis of pneumonia was established in 336 (51%) patients. The rate of etio-
logic diagnosis and polymicrobial etiology was higher in patients from the IMV group
Fig 1. Flow diagram of the study population.
https://doi.org/10.1371/journal.pone.0191721.g001
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(Table 4). Streptococcus pneumoniae was the main pathogen and did not differ between both
groups. Legionella pneumophila was less frequent in patients from the IMV group.
Length of stay and outcome variables
The overall 30-day mortality rate was 145 (22%). The ICU and hospital stay were longer, and
the 30-day mortality higher, in patients from the IMV group (Table 5).
Among different variables associated with 30-day mortality in the univariate analysis
(Table 6), IMV was independently associated with increased 30-day mortality in the multivari-
ate analysis, together with septic shock, lower PaO2/FiO2 ratio, and higher levels of serum K
+.
The area under the ROC curve of the model to predict 30-day mortality was 078 (95% CI 070
to 086).
The actual mortality of the IMV group was higher than that predicted by the APACHE-II
score (33% vs. 26%, respectively). In contrast, the actual mortality of patients without IMV was
lower than that predicted by this score (18% vs. 23.5%, respectively).
Among SCAP patients we distinguished those who met the major criteria from those who
met the minor criteria only, according to IDSA/ATS 2007 definition. The mortality of patients
with at least one major severity criteria was higher than that of patients with minor criteria
only (86, 29% vs. 59, 16%, p<0.001). The actual mortality of patients with septic shock and
those with IMV alone was higher than that predicted by the APACHE-II score, while for
patients without major severity criteria, the actual mortality was lower than that predicted by
this score (Table 7). Mortality was highest in patients with both septic shock and IMV.
Table 2. General characteristics of the study population.
Variable No IMV
n = 510
IMV
n = 154
p-value
Age (years) 72±16 66±16 <0001
Sex (male) 337 (66) 103 (67) 085
Current or former smoking 308 (61) 91 (62) 091
Current or former alcohol abuse 115 (23) 42 (29) 014
Intravenous drug abuse 2 (04) 1 (1) 066
Previous antibiotics 114 (24) 20 (15) 0033
Influenza vaccine 202 (49) 30 (36) 0030
Pneumococcal vaccine 61 (15) 12 (14) 081
Previous inhaled corticosteroids 107 (21) 21 (14) 0060
Previous systemic corticosteroids 12 (3) 6 (5) 021
Co-morbidities:
Chronic respiratory disease  217 (43) 63 (41) 071
Chronic cardiovascular disease ± 116 (23) 38 (25) 059
Diabetes mellitus 116 (24) 34 (23) 090
Chronic neurological disease 125 (25) 33 (22) 049
Chronic renal disease 62 (12) 16 (11) 059
Chronic liver disease 26 (5) 12 (8) 021
Results are given as n (%) or mean±SD. Percentages calculated on non-missing data.
 Chronic respiratory disease includes chronic obstructive pulmonary disease, asthma, bronchiectasis, and sequelae of
pulmonary tuberculosis.
± Chronic cardiovascular disease includes coronary artery disease, hypertensive or valvular heart diseases, and dilated
myocardial disease of any cause. IMV = invasive mechanical ventilation; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0191721.t002
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The overall rate of ICU admission was 363 (55%), and was higher in patients with IMV
(Table 5). In patients without IMV, those admitted to the ICU had lower 30-day mortality
than those no admitted to the ICU (Table 8). Regarding severity characteristics of non-intu-
bated patients, the ICU patients had more frequently septic shock, bacteremia, PaO2/FiO2
250, and multilobar radiologic infiltrates than non-ICU patients. In contrast, non-ICU
patients were older, had more frequently confusion/disorientation, acute and chronic renal
failure, and chronic cardiovascular and neurological disease, and higher APACHE-II score
and PSI and CURB-65 risk classes. After adjustment for potential confounders, ICU admission
in non-intubated patients was not significantly associated with lower 30-day mortality
(adjusted OR 077, 95% CI 036 to 162, p = 049).
Discussion
We studied patients with SCAP independently from the site of care, with particular emphasis
on the use of IMV. The main findings of this study are: 1) patients invasively ventilated had a
Table 3. Characteristics of pneumonia at hospital admission.
Variable No IMV
n = 510
IMV
n = 154
p-value
Vital signs at hospital admission:
Respiratory rate (breaths/min) 32±8 31±10 032
Heart rate (beats/min) 101±21 111±23 <0001
Systolic blood pressure (mmHg) 123±32 128±36 0090
Diastolic blood pressure (mmHg) 68±16 73±19 0006
Laboratory data at hospital admission:
Creatinine (mg/dL) 17±10 17±11 081
C-reactive protein (mg/dL) 21±13 22±14 059
White blood cells (109 cell/L) 150±93 135±75 0066
Hematocrite (%) 40±6 38±8 0055
Platelets (109 cell/L) 241±103 265±155 016
PaO2/FiO2 (mmHg) 236±66 213±84 0005
PaCO2 (mmHg) 37±13 43±17 <0001
Arterial pH 742±009 736±013 <0001
Serum Na+ (mEq/L) 136±6 135±6 020
Serum K+ (mEq/L) 41±08 40±08 011
Severity variables at hospital admission:
APACHE-II 16±5 17±6 0091
PSI risk class IV-V 424 (83) 125 (81) 057
CURB-65 risk score 3–5 322 (63) 76 (49) 0002
Confusion/disorientation 245 (48) 73 (47) 089
Bacteremia 71 (14) 25 (16) 048
Multilobar infiltration 231 (45) 65 (42) 050
Pleural effusion 69 (14) 39 (26) 0001
Acute renal failure 290 (57) 67 (44) 0004
Septic shock 140 (28) 58 (38) 0015
Results are given as n (%) or mean±SD. Percentages calculated on non-missing data.
APACHE = acute physiology and chronic health evaluation; CURB-65 = confusion, elevated blood urea nitrogen,
respiratory rate and blood pressure plus age65 years; IMV = invasive mechanical ventilation; PSI = pneumonia
severity index; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0191721.t003
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high 30-day mortality rate, 33%; and 2) IMV, together with septic shock, worse hypoxemia
and increased serum potassium, was independently associated with increased mortality.
Despite recent advances, pneumonia remains the main cause of death from infection in
developed countries [22]. Several studies have identified that patients with respiratory failure
Table 4. Microbial etiology of the study population.
Pathogen No IMV
n = 510
IMV
n = 154
p-value
Patients with defined etiology 245 (48) 91 (59) 0016
Streptococcus pneumoniae 135 (55) 51 (56) 098
with bacteremia 52 (10) 18 (12) 076
Legionella pneumophila 23 (9) 2 (2) 0046
Respiratory viruses 34 (14) 19 (21) 016
Atypical bacteria 17 (7) 3 (3) 032
Chlamydophila pneumoniae 6 (2) 1 (1) 073
Mycoplasma pnemoniae 6 (2) 2 (2) 079
Coxiella burnetti 6 (2) 0 (0) 030
Staphylococcus aureus 12 (5) 8 (9) 027
Pseudomonas aeruginosa 18 (7) 7 (8) 090
Haemophilus influenzae 8 (3) 8 (9) 0068
Escherichia coli 10 (4) 3 (3) 099
Other Streptococcus species 3 (1) 2 (2) 088
Klebsiella pneumoniae 3 (1) 0 (0) 068
Moraxella catarrhalis 3 (1) 1 (1) 064
Other microorganisms 13 (5) 8 (9) - - -
Polymicrobial 35 (14) 22 (24) 0047
Results are given as n (%). Percentages calculated on non-missing data. The percentages of pathogens are related to
the number of patients with etiologic diagnosis in each group, except for bacteremia due to Streptococcus
pneumoniae, which is calculated related to the total number of patients in each group.
IMV = invasive mechanical ventilation.
https://doi.org/10.1371/journal.pone.0191721.t004
Table 5. Site of admission, length of stay, treatment adequacy and outcome variables.
Variable No IMV
n = 510
IMV
n = 154
p-value
ICU admission  210 (41) 153 (99) † <0001
ICU stay (days) ‡ 4 (3;7) 10 (6;19) <0001
Hospital stay (days) 10 (7;14) 20 (12;33) <0001
Adequate empiric treatment § 199 (92) 75 (89) 051
30-day mortality 94 (18) 51 (33) <0001
Results are given as n (%) or median (interquartile range). Percentages are calculated on non-missing data.
 Intermediate care units are also included.
† The patient of the IMV group not admitted to ICU was extubated in the emergency room.
‡ Data calculated for patients admitted to an ICU only.
§ Data calculated for patients with defined bacterial etiology only.
ICU = intensive care unit; IMV = invasive mechanical ventilation; NIV = non-invasive ventilation; SD = standard
deviation.
https://doi.org/10.1371/journal.pone.0191721.t005
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Table 6. Significant univariate and multivariate weighted logistic regression analyses for the prediction of 30-day mortality.
Variable Univariate Multivariate 
OR 95% CI p-value OR 95% CI p-value
Age (+10 yrs.) 135 117 to 154 <0001 - - -
Tobacco consumption - - -
No 1 - - - - -
Former 076 050 to 115 019 - - -
Current 048 028 to 081 0006 - - -
Alcohol abuse
No 1 - - - - -
Former 029 009 to 097 0044 - - -
Current 074 045 to 124 025 - - -
APACHE-II at admission 105 101 to 110 0028 - - -
Chronic cardiovascular disease 177 117 to 266 0006 - - -
Chronic liver disease 193 096 to 387 0061 - - -
Chronic neurologic disease 277 186 to 413 <0001 - - -
Mental confusion 162 112 to 235 0011 - - -
Shock 174 118 to 255 0005 340 138 to 836 0008
PSI risk classes IV-V 305 159 to 586 <0001 - - -
CURB-65 score 3–5 186 125 to 277 0002 - - -
Serum Creatinine (+1 mg/dL) 121 103–143 0023 - - -
Platelets (+100 x 109 cell/L) 122 102 to 147 0034 - - -
PaO2/FiO2 (+10 mmHg) 0.97 0.95 to 1.00 0.079 092 086 to 098 0011
Serum Na+ (+1 mEq/L) 103 100 to 106 0044 - - -
Serum K+ (+1 mEq/L) 136 107–173 0012 254 132 to 490 0005
Arterial pH (+0.1 units) 078 066 to 093 0006
Invasive mechanical ventilation 218 144–331 <0001 354 145 to 867 0006
 Summary statistics of the multivariate model: Pearson chi-square test, value / df = 093; AIC value = 14451.
AIC = Akaike’s information criterion; APACHE = acute physiology and chronic health evaluation; CI = confidence interval; CURB-65 = confusion, elevated blood urea
nitrogen, respiratory rate and blood pressure plus age65 years; df = degrees of freedom; OR = odds ratio; PSI = pneumonia severity index.
https://doi.org/10.1371/journal.pone.0191721.t006
Table 7. Mortality, severity at admission and length of stay for patients with and without major severity criteria.
Variable No shock or IMV
n = 370
Shock alone
n = 140
IMV alone
n = 96
IMV and shock
n = 58
p-value
30-day mortality 59 (16) 35 (25) 29 (30) 22 (38) <0001
APACHE-II at admission 16±6 15±5 15±5 19±5 <0001
Mortality predicted by APACHE-II 235% 21% 21% 32% - - -
ICU stay (days) † 5 (3;7) 3 (2;6) 10 (5;19) 11 (7;20) <0001
Hospital stay (days) 10 (7;14) 9 (6;16) 18 (12;32) 21 (13;35) <0001
Data are n (%), mean±SD or median (interquartile range). Percentages are calculated on non-missing data.
 Intermediate care units are also included.
† Data calculated for patients admitted to an ICU only. APACHE = acute physiology and chronic health evaluation; ICU = intensive care unit; IMV = invasive
mechanical ventilation.
https://doi.org/10.1371/journal.pone.0191721.t007
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and IMV, severe sepsis/septic shock, and decompensated co-morbidities are at greater risk of
death [2,6,23–25].
The use of IMV is a major determinant for ICU admission in patients with CAP [1,3].
Between 37% and 60% patients with CAP in the ICU may require IMV [3,26–28]. The
Table 8. Characteristics of patients not subjected to invasive mechanical ventilation divided into those admitted
and those not admitted to the intensive care unit.
Variable Non-ICU
patients
n = 300
ICU
patients
n = 210
p-value
Age (years) 77±14 66±17 <0001
Sex (male) 202 (67) 135 (64) 047
Co-morbidities:
Chronic respiratory disease  121 (40) 96 (46) 023
Chronic cardiovascular disease ± 81 (27) 35 (17) 0006
Diabetes mellitus 71 (25) 45 (22) 046
Chronic neurological disease 98 (33) 27 (13) <0001
Chronic renal disease 48 (16) 14 (7) 0001
Chronic liver disease 13 (4) 13 (6) 036
Major and minor severity criteria: [1]
Septic shock 71 (24) 69 (33) 0022
PaO2/FiO2 250
 164 (55) 140 (67) 0007
Respiratory rate30 breaths/min ‡ 175 (58) 125 (60) 079
Creatinine level >15 mg/dL 188 (63) 102 (49) 0002
Confusion/disorientation 159 (53) 86 (41) 0007
Multilobar radiologic infiltrates 125 (42) 106 (51) 0049
Hypotension (not meeting septic shock criteria) 42 (14) 41 (20) 0096
Core temperature <36˚C 35 (12) 23 (11) 080
White blood cell counts <4,000 cells/mm3 15 (5) 18 (9) 011
Platelet count <100,000 cells/mm3 12 (4) 5 (2) 032
Other severity variables at hospital admission:
APACHE-II 16±5 15±5 0036
PSI risk class IV-V 261 (87) 163 (78) 0005
CURB-65 risk score 3–5 209 (70) 113 (54) <0001
Bacteremia 33 (11) 38 (18) 0023
Hospital stay (days) 8 (6;12) 12 (9;16) <0001
Adequate empiric treatment § 95 (93) 104 (90) 047
30-day mortality 70 (23) 24 (11) 0001
Data are n (%), mean±SD or median (interquartile range). Percentages calculated on non-missing data.
 Chronic respiratory disease includes chronic obstructive pulmonary disease, asthma, bronchiectasis, and sequelae of
pulmonary tuberculosis.
± Chronic cardiovascular disease includes coronary artery disease, hypertensive or valvular heart diseases, and dilated
myocardial disease of any cause.
‡ The use of non-invasive mechanical ventilation can substitute for respiratory rate30 breaths/min or PaO2/FiO2
250 [1].
§ Data calculated for patients with defined bacterial etiology only.
IMV = invasive mechanical ventilation; SD = standard deviation. APACHE = Acute Physiology And Chronic Health
Evaluation; PSI = pneumonia severity index; CURB-65 = Confusion, elevated blood Urea nitrogen, Respiratory rate
and Blood pressure plus age65 years.
https://doi.org/10.1371/journal.pone.0191721.t008
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mortality rates of ICU patients with CAP ranged between 13% and 28%, depending on the dif-
ferent series and whether ICU or hospital mortality was reported. Although IMV was signifi-
cantly associated with increased ICU mortality in patients with SCAP [26,27], a multivariate
analysis found that IMV was not an independent prognostic factor among these ICU patients
[26].
Several studies have assessed the outcomes of patients with CAP that require IMV [29–32].
These studies were retrospective or, in one case, prospective historic data were analyzed [30],
and included a limited number of patients, ranging between 85 and 124. The mortality rate of
these ventilated patients was high, 32% and 55% for ICU mortality [29,32], and 46% and 56%
for hospital mortality [30,31]. Even in patients with CAP treated with NIV, the hospital mor-
tality of those intubated after NIV failure may be as high as 54% [33]. As expected, older age,
co-morbidities, and higher severity indices of pneumonia and organ system dysfunction at
admission were independently associated with mortality in these reports. These studies, how-
ever, did not assess whether the use of IMV was simply a marker of more acute severe disease
or was a determinant of poor outcome.
To our knowledge, the present study has assessed for the first time the characteristics of a
large, prospective and consecutive series of hospitalized patients with SCAP with special focus
in the association of IMV with mortality. Compared to non-intubated patients, those who
received IMV did not present higher severity scores at hospital admission according to APA-
CHE-II, PSI or CURB-65 scores. However, the use of IMV independently predicted 30-day
mortality. The contribution of IMV to mortality is reinforced by the finding that the actual
mortality of these patients was higher than that predicted by the APACHE-II score. In con-
trast, the actual mortality of non-intubated patients was lower than that predicted by this
score. Whatever the cause is, the use of IMV seems to give a surplus of mortality in this sub-
group of SCAP patients. Based on these results, PSI, CURB-65, or APACHE-II scores were less
suitable than IMV for a reliable identification of SCAP patients at higher risk for mortality in
our population.
Septic shock was also an independent predictor of mortality in patients with SCAP. This is
not surprising considering that shock is an accepted major severity criterion of CAP and that
it is associated with clinical failure [34].
We think that the strong and independent association of both major criteria with mortality,
particularly IMV or the combination of both, would serve in the selection of very severe popu-
lations for future trials that would test new antibiotics or co-adjuvant therapies for SCAP [35].
The majority of patients with SCAP did not require intubation and IMV. The higher
CURB-65 in non-intubated patients reflects an older population with more frequent acute
renal failure at admission, two major components of this score. Patients without IMV were
also characterized by a lower rate of defined microbial etiology; this is not surprising if we con-
sider that lower respiratory tract samples are easily obtained in intubated patients.
Non-intubated patients were admitted to the ICU preferentially for septic shock, worse
hypoxemia or multilobar involvement. The more severe presentation of pneumonia did not
result in a higher mortality in this group compared to non-intubated patients admitted to a
general ward. This is probably due to a proper monitoring and treating in the ICU-group, as
well as to the older age, and the more frequent cardiovascular and neurological diseases in the
non-ICU group; all these variables were independent predictors for mortality in this popula-
tion, regardless the severity of pneumonia presentation. This may explain why ICU admission
of non-intubated patients with SCAP was not associated with different mortality when poten-
tial confounders were considered.
In our opinion, the most important strengths of this study are the large number of patients
recruited, the prospective and consecutive collection of data, the focus on intubated and non-
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intubated patients, and the statistical analysis for the prediction of mortality, with the IPTWs
used to account for biases due to observed confounders and the propensity score. There are,
however, some limitations to be addressed. First, the long period of recruitment, 12 years,
since the care of patients could have evolved during this time. However, our protocol for man-
aging CAP did not change substantially during these years. Second, this study was conducted
in a single centre and therefore the extrapolation of these findings to other settings must be
done cautiously. Third, complete information on the type, number and duration of previous
antibiotic treatment was not collected.
In conclusion, IMV independently predicted 30-day mortality in patients with SCAP.
Patients invasively ventilated should be considered a different population with higher mortal-
ity for future clinical trials on new interventions addressed to improve mortality of SCAP.
Supporting information
S1 File. Database.sav.
(SAV)
Acknowledgments
We are indebted to all medical and nursing colleagues from the participating ICUs for their
assistance and cooperation in this study, and to Prof. Richard K. Albert for his valuable advice
in the conception of this study.
Author Contributions
Conceptualization: Miquel Ferrer, Catia Cilloniz, Adamantia Liapikou, Francesco Blasi,
Antoni Torres.
Formal analysis: Chiara Travierso, Albert Gabarrus, Otavio T. Ranzani.
Investigation: Miquel Ferrer, Chiara Travierso, Catia Cilloniz, Eva Polverino, Adamantia Lia-
pikou, Francesco Blasi, Antoni Torres.
Methodology: Miquel Ferrer, Catia Cilloniz, Albert Gabarrus, Eva Polverino, Francesco Blasi.
Resources: Chiara Travierso, Eva Polverino, Adamantia Liapikou, Antoni Torres.
Supervision: Miquel Ferrer, Catia Cilloniz, Francesco Blasi, Antoni Torres.
Validation: Miquel Ferrer, Antoni Torres.
Writing – original draft: Miquel Ferrer, Chiara Travierso, Catia Cilloniz, Otavio T. Ranzani,
Adamantia Liapikou, Francesco Blasi, Antoni Torres.
Writing – review & editing: Miquel Ferrer, Chiara Travierso, Catia Cilloniz, Adamantia Liapi-
kou, Francesco Blasi, Antoni Torres.
References
1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al Infectious Diseases
Society of America/American Thoracic Society consensus guidelines on the management of commu-
nity-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27–S72.
2. Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired
pneumonia. Intensive Care Med 2011; 37: 214–23. https://doi.org/10.1007/s00134-010-2077-0 PMID:
21080155
3. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R, et al. Severe Community-Acquired
Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society
Mechanical ventilation in severe pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0191721 January 25, 2018 12 / 14
Guidelines to Predict an Intensive Care Unit Admission. Clin Infect Dis 2009; 48: 377–85. https://doi.
org/10.1086/596307 PMID: 19140759
4. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with
community-acquired pneumonia is associated with higher mortality. Chest 2010; 137: 552–57. https://
doi.org/10.1378/chest.09-1547 PMID: 19880910
5. Alvarez-Lerma F, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care 2004; 10:
369–74. PMID: 15385753
6. Pierson DJ. Indications for mechanical ventilation in adults with acute respiratory failure. Respir Care
2002; 47: 249–62. PMID: 11874605
7. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867–
903. https://doi.org/10.1164/ajrccm.165.7.2105078 PMID: 11934711
8. Pinhu L, Whitehead T, Evans T, Griffiths M. Ventilator-associated lung injury. Lancet 2003; 361: 332–
40. https://doi.org/10.1016/S0140-6736(03)12329-X PMID: 12559881
9. Leeper KV Jr., Torres A. Community-acquired pneumonia in the intensive care unit. Clin Chest Med
1995; 16: 155–71. PMID: 7768089
10. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the Management of
Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J
Respir Crit Care Med 2005; 171: 388–416. https://doi.org/10.1164/rccm.200405-644ST PMID:
15699079
11. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J, et al. Pneumonia severity index class
v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity
scores. Chest 2007; 132: 515–22. https://doi.org/10.1378/chest.07-0306 PMID: 17505026
12. Ferrer M, Esquinas A, Leon M, Gonzalez G, Alarcon A, Torres A. Noninvasive ventilation in severe hyp-
oxemic respiratory failure: A randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438–44.
https://doi.org/10.1164/rccm.200301-072OC PMID: 14500259
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II a severity of disease classification sys-
tem. Crit Care Med 1985; 13: 818–29. PMID: 3928249
14. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify
low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50. https://doi.
org/10.1056/NEJM199701233360402 PMID: 8995086
15. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56:
iv1–iv64. PMID: 11713364
16. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community
acquired pneumonia severity on presentation to hospital: an international derivation and validation
study. Thorax 2003; 58: 377–82. https://doi.org/10.1136/thorax.58.5.377 PMID: 12728155
17. Cilloniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrus A, et al. Microbial aetiology of com-
munity-acquired pneumonia and its relation to severity. Thorax 2011; 66: 340–346. https://doi.org/10.
1136/thx.2010.143982 PMID: 21257985
18. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall; 1989.
19. Thoemmes F, Ong AD. A Primer on Inverse Probability of Treatment Weighting and Marginal Structural
Models. Emerg Adulthood 2016; 4: 40–49.
20. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for pro-
pensity score models. Am J Epidemiol 2006; 163: 1149–56. https://doi.org/10.1093/aje/kwj149 PMID:
16624967
21. Fahmeir L, Tutz G. Multivariate statistical modeling based on generalized linear models. New York:
Springer Verlag; 1994.
22. Mongardon N, Max A, Bougle A, Pene F, Lemiale V, Charpentier J, et al. Epidemiology and outcome of
severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care 2012;
16: R155. https://doi.org/10.1186/cc11471 PMID: 22894879
23. Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman AI. Severe community-acquired pneu-
monia: what’s in a name? Curr Opin Infect Dis 2003; 16: 153–59. PMID: 12734448
24. Ferrer M, Cosentini R, Nava S. The use of non-invasive ventilation during acute respiratory failure due
to pneumonia. Eur J Intern Med 2012; 23: 420–428. https://doi.org/10.1016/j.ejim.2012.02.011 PMID:
22726370
25. Kolditz M, Ewig S, Klapdor B, Schutte H, Winning J, Rupp J, et al. Community-acquired pneumonia as
medical emergency: predictors of early deterioration. Thorax 2015; 70: 551–58. https://doi.org/10.
1136/thoraxjnl-2014-206744 PMID: 25782758
Mechanical ventilation in severe pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0191721 January 25, 2018 13 / 14
26. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, et al. A five-year study of severe
community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care
unit. Intensive Care Med 1995; 21: 24–31. PMID: 7560469
27. Bodi M, Rodriguez A, Sole-Violan J, Gilavert MC, Garnacho J, Blanquer J, et al. Antibiotic prescription
for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Dis-
eases Society of America guidelines on survival. Clin Infect Dis 2005; 41: 1709–16. https://doi.org/10.
1086/498119 PMID: 16288392
28. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired
pneumonia patients admitted to the ward and the ICU. Chest 2008; 133: 610–617. https://doi.org/10.
1378/chest.07-1456 PMID: 17989157
29. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Palizas F, Gonzalez M, et al. Prognosis factors and
outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 2005; 20:
230–238. https://doi.org/10.1016/j.jcrc.2005.05.010 PMID: 16253791
30. Pascual FE, Matthay MA, Bacchetti P, Wachter RM. Assessment of prognosis in patients with commu-
nity-acquired pneumonia who require mechanical ventilation. Chest 2000; 117: 503–12. PMID:
10669697
31. Lee JH, Ryu YJ, Chun EM, Chang JH. Outcomes and prognostic factors for severe community-acquired
pneumonia that requires mechanical ventilation. Korean J Intern Med 2007; 22: 157–63. https://doi.org/
10.3904/kjim.2007.22.3.157 PMID: 17939332
32. Aydogdu M, Ozyilmaz E, Aksoy H, Gursel G, Ekim N. Mortality prediction in community-acquired pneu-
monia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores.
Tuberk Toraks 2010; 58: 25–34. PMID: 20517726
33. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, et al. Non-
invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive
Care Med 2012; 38: 458–66. https://doi.org/10.1007/s00134-012-2475-6 PMID: 22318634
34. Aliberti S, Amir A, Peyrani P, Mirsaeidi M, Allen M, Moffett BK, et al. Incidence, etiology, timing, and risk
factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008;
134: 955–62. https://doi.org/10.1378/chest.08-0334 PMID: 18583514
35. Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Schliephake DE, et al. Concept for a study design in
patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-
enriched immunoglobulin preparation—The CIGMA study. Respir Med 2015; 109: 758–67. https://doi.
org/10.1016/j.rmed.2015.03.008 PMID: 25887136
Mechanical ventilation in severe pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0191721 January 25, 2018 14 / 14
